Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 15/20 | 0.84 |
| ▸ | EPAS1 | Q99814 | 15/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesuol SCHEMBL29258072 | 0.93 | HIF1A (0.84) | HIF1AEPAS1ABCG2 | |
| SCHEMBL6907224 | 0.91 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL31237267 | 0.91 | HIF1A (1.00) | HIF1AEPAS1 | |
| Isomammeisin SCHEMBL6914103 | 0.88 | HIF1A (1.00) | HIF1AEPAS1ABCG2 | |
| SCHEMBL6914633 | 0.84 | HIF1A (1.00) | HIF1AEPAS1 | |
| Mammeisin SCHEMBL6913744 | 0.84 | HIF1A (1.00) | HIF1AEPAS1ABCG2 | |
| Mammeisin SCHEMBL31237557 | 0.84 | HIF1A (1.00) | HIF1AEPAS1ABCG2 | |
| SCHEMBL29517160 | 0.77 | HIF1A (0.60) | HIF1AEPAS1 | |
| SCHEMBL29934508 | 0.74 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL30377279 | 0.73 | HIF1A (0.78) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105419-A | Blood sugar reducing active part and active chemical component of clematis filifolia leaves and application thereof | 中国科学院昆明植物研究所 | 2024-05-31 | — | — | CN | disclosed |
| US-9556138-B2 | Method of treatment for acne and an anti-acne formulation | Piramal Enterprises Limited (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9556138-B2 | Method of treatment for acne and an anti-acne formulation | Piramal Enterprises Limited (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20150011619-A1 | METHOD OF TREATMENT FOR ACNE AND AN ANTI-ACNE FORMULATION | Piramal Enterprises Limited (IN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011619-A1 | METHOD OF TREATMENT FOR ACNE AND AN ANTI-ACNE FORMULATION | PROC, HSD17B10, CYP19A1 | HIF1A 3711/4885EPAS1 4447/4885MAPT 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.